Sonrotoclax( —— )

Catalog No. M36604 CAS No. 2383086-06-2

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Sonrotoclax
Note

Research use only, not for human use.
Brief Description

Sonrotoclax is a potent, orally active inhibitor of Bcl2, demonstrating effective cell-killing activity against a range of lymphoma and leukemia cell lines .
Description

Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines.
In Vitro

——
In Vivo

Animal Model:Female NCG mice with acute lymphoblastic leukemia (ALL) xenografts Dosage:5, 15, 50 mg/kg Administration:oral administration; daily, for 42 days Result:Inhibited tumor growth in a dose-dependent manner.
Synonyms

——
Pathway

Angiogenesis
Target

Bcl-2
Recptor

BCL
Research Area

——
Indication

——

CAS Number

2383086-06-2
Formula Weight

890.1
Molecular Formula

C49H59N7O7S
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (112.35 mM; Ultrasonic )
SMILES

CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC([N+]([O-])=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C
Chemical Name

——

1. Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1.

Calculator

molnova catalog